Program
Anti-CD70 CAR-expressing T Lymphocytes
Also written as “CD70 CAR-T cells” and “BCMA/CD70 CAR-T cells”.
Its studies are mostly in Neoplasm Metastasis · Lupus Erythematosus, Systemic · Ovarian Neoplasms · Carcinoma, Renal Cell, led by Chongqing Precision Biotech.
Furthest: phase 1, since Jun 12, 20226 company-led studies, 6 open or runningNext primary completion: Dec 31, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chongqing Precision Biotech | 66 open or running | phase 1since Jun 12, 2022 | Jun 12, 2022 | Dec 31, 2026phase 1 · NCT06215950 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 12, 2022First studies: 2 phase 1 studies in Neoplasm MetastasisFirst studyNCT05420545, NCT05420519
- Jul 19, 2022Phase 1 study in Neoplasm MetastasisNCT05468190 · 48 planned · China
- Aug 18, 2023Phase 1 study in Carcinoma, Renal CellNCT06010875 · 48 planned · China
- Jan 11, 2024Phase 1 study in Ovarian NeoplasmsNCT06215950 · 36 planned · China
- Dec 11, 2025Phase 1 study in Lupus Erythematosus, SystemicNCT07318259 · 18 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 1 study in Ovarian NeoplasmsNCT06215950
TargetBeta
CD70 →read by rule
“A preparation of human T-lymphocytes transduced with a recombinant viral vector encoding a chimeric T-cell receptor (chimeric antigen receptor or CAR) consisting of one or more binding domains that target the tumor-associated antigen (TAA) CD70 (CD27 ligand; tumor necrosis factor superfamily member ”NCIt, by rule
Other programs on CD70
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-CD70/CD3 Bispecific Antibody INCA036873rule | Incyte | phase 1 | 1 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07318259Lupus Erythematosus, Systemic · China | 1 | Recruiting | Jul 2026 | 18 |
| NCT06215950Ovarian Neoplasms · China | 1 | Recruiting | Dec 31, 2026 | 36 |
| NCT06010875Carcinoma, Renal Cell · China | 1 | Recruiting | Dec 31, 2025 | 48 |
| NCT05468190Neoplasm Metastasis · China | 1 | Recruiting | Jul 17, 2024 | 48 |
| NCT05420545Neoplasm Metastasis · China | 1 | Recruiting | Dec 31, 2023 | 36 |
| NCT05420519Neoplasm Metastasis · China | 1 | Recruiting | Dec 31, 2023 | 24 |
How it is read
Names in the registry
- “CD70 CAR-T cells”, 9 entries
- “BCMA/CD70 CAR-T cells”, 1 entry
Conditions, from the studies’ own filings
- Neoplasm Metastasis, 3 studies
- Lupus Erythematosus, Systemic, 1 study
- Ovarian Neoplasms, 1 study
- Carcinoma, Renal Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.